MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
16 mai 2024 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis...
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
16 mai 2024 08h00 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
15 mai 2024 16h05 HE
|
Athira Pharma, Inc.
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Global Flow Cytometry Market Report 2024-2029, Featuring Agilent Technologies, BD, Bio-Rad Laboratories, Cytek Biosciences, Danaher, Miltenyi Biotec, Sony Biotechnology and Standard Biotools
15 mai 2024 09h48 HE
|
Research and Markets
Dublin, May 15, 2024 (GLOBE NEWSWIRE) -- The "Flow Cytometry: Products, Technologies and Global Markets 2024-2029" report has been added to ResearchAndMarkets.com's offering. The global market...
Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa
15 mai 2024 08h52 HE
|
Stereotaxis, Inc.
Stereotaxis presents innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablati
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map
15 mai 2024 08h00 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces its intent to commercialize the patented assay...
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
15 mai 2024 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology...
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
14 mai 2024 16h15 HE
|
Lumos Pharma, Inc.
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201...
Ocugen Provides Business Update with First Quarter 2024 Financial Results
14 mai 2024 08h00 HE
|
Ocugen
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market...
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
14 mai 2024 08h00 HE
|
Compass Therapeutics
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...